<DOC>
	<DOCNO>NCT00464607</DOCNO>
	<brief_summary>Purpose study evaluation tolerability ( local systemic ) clinical efficacy ( term oocytes recover ) subcutaneously versus intramuscularly administer Merional® ( IBSA , Lugano – CH ) patient undergo controlled ovarian hyperstimulation ( COH ) ART programme ( IVF ) .</brief_summary>
	<brief_title>Prospective , Randomized , Controlled , Clinical Study Tolerability Efficacy hMG-IBSA</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<criteria>Female patient age 20 40 year undergoing ovarian stimulation purpose oocyte retrieval assist conception programme Body Mass Index ( BMI ) 2028 kg/m2 early follicular phase FSH level &lt; 9 IU/l . ascertain presumptive hypersensitivity active principle and/or ingredient primary ovarian failure ovarian cyst enlargement due polycystic ovarian syndrome oocyte donation abnormal bleeding undetermined origin patient exhibit poor response require dos 300 IU daily previous treatment cycle receive similar therapy ( previous treatment cycle ) 30 day prior begin present study uncontrolled thyroid adrenal dysfunction neoplasia severe impairment renal and/or hepatic function diabetes active thrombophlebitis , cardiopathy epilepsy presence clinically significant systemic disease contraindication pregnant and/or carry pregnancy term presence anatomical abnormality reproductive system pregnant breastfeeding menopause</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>